CAR-T therapy is set to revolutionize oncology pipelines and mark a new era for personalized medicine. With the recent approvals of Yescarta and Kymriah and the $11 billion acquisition of Kite, the race is on to lead the commercialization of safe, efficacious and accessible CAR-T therapy.

The fourth annual CAR-T congress USA provides a platform for emerging novel data in small scale clinical trials ran by the leading academic institutions, including MD Anderson and the University of Pennsylvania.

Hear first-hand, the emerging areas of research from new companies into single patient experiences, as well as context around patient relapses and methods of toxicity management.

Join thought leaders from biotechs, pharmaceutical companies and academia to address the challenges of CAR-T therapy including toxicity, scalability and efficacy in both liquid and solid tumours.

Discover how CAR-T compares to standard treatments and advances in genome editing tools, the new methods in allogeneic and autologous process development and the pre-clinical concepts that will pave the way for novel antigen discovery.

Be part of the movement that engineers a strategy to reprogram the cancer treatments we know today.

Book before January 25 to save up to $800.  To learn more about this event and to book online visit: www.car-tcongress.com/register